Minerva Neurosciences (NASDAQ:NERV) Given “Neutral” Rating at HC Wainwright

HC Wainwright restated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com began coverage on shares of Minerva Neurosciences in a research report on Saturday, November 2nd. They set a “sell” rating for the company.

Minerva Neurosciences Trading Down 2.1 %

Minerva Neurosciences stock opened at $2.31 on Wednesday. The stock has a market cap of $16.15 million, a P/E ratio of -0.52 and a beta of 0.18. The company has a 50-day moving average price of $2.64 and a 200 day moving average price of $2.79. Minerva Neurosciences has a 12-month low of $2.26 and a 12-month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). As a group, analysts forecast that Minerva Neurosciences will post -2.26 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.